Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk

Evaluate satisfaction in people treated with IPDE5 inhibitors over time

Completed

Looking for future studies?

Key information

Conditions

Erectile Dysfunction Behavior Genital Diseases Genital Diseases, Male Male Urogenital Diseases Mental Disorders Personal Satisfaction Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Urogenital Diseases

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

About this study

12 first patients that are eligible

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CV risk factors
Male above 18

Exclusion criteria

Non-informed consent

Treatment and study plan

Primary outcomes

EDITS

Time frame: 6 months
SEAR

Time frame: 6 months

Secondary outcomes

Medication prescribed

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Industry

Registry information

Official study title

Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.

Acronym: TIERRA

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Apr 2, 2009
Registry last updated: Feb 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed